## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESM

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104

Expires: December 31, 2014

Estimated average burden

0.5

hours per

response

1. Name and Address of Reporting Person*	2. Date of Event Requiring Statement (Month/Day/Year) 09/16/2014	Issuer Name and Ticker or Trading Symbol     Tokai Pharmaceuticals Inc [TKAI]			
Thomas Robert Bain		4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Last) (First) (Middle) C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)		Check all applicable     Director			

Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Excercise	5. Ownership Form: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr.				
	Date Exercisable	Expiration Date	Title	Amount or Number of SharesM	Price of Derivative Security	or Indirect (I) (Instr. 5)	5)				
Series B-2 Preferred Stock	(1)	(1)	Common Stock	5,469	<b>\$</b> (1)	I	See footnote. (2)				
Series C Preferred Stock	(3)	(3)	Common Stock	19,009	<b>\$</b> (3)	I	See footnote. (2)				
Series D-1 Preferred Stock	(4)	(4)	Common Stock	8,308	\$ (4)	I	See footnote. (2)				
Series D-2 Preferred Stock	(5)	(5)	Common Stock	1,701	<b>\$</b> <sup>(5)</sup>	I	See footnote. (2)				
Series D-3 Preferred Stock	(6)	(6)	Common Stock	26,273	<b>\$</b> <sup>(6)</sup>	I	See footnote. (7)				
Series E Preferred Stock	(8)	(8)	Common Stock	76,534	\$ (8)	I	See footnote. (2)				

## **Explanation of Responses:**

- 1. The Series B-2 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- 2. Robert Thomas as Trustee of the R.B. Thomas Superannuation Fund.
- 3. The Series C Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- 4. The Series D-1 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- 5. The Series D-2 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- 6. The Series D-3 Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- 7. Robert Thomas as Trustee of the R.B. Thomas Family Trust.
- 8. The Series E Preferred Stock is convertible into Common Stock on a 10.47-for-one basis into the number of shares of Common Stock shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date.

/s/ Robert B. Thomas 09/12/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.